CO2024008188A2 - Terapia génica para deficiencias relacionadas con lámina a - Google Patents

Terapia génica para deficiencias relacionadas con lámina a

Info

Publication number
CO2024008188A2
CO2024008188A2 CONC2024/0008188A CO2024008188A CO2024008188A2 CO 2024008188 A2 CO2024008188 A2 CO 2024008188A2 CO 2024008188 A CO2024008188 A CO 2024008188A CO 2024008188 A2 CO2024008188 A2 CO 2024008188A2
Authority
CO
Colombia
Prior art keywords
aav
hlamina
raav
itr
vector genome
Prior art date
Application number
CONC2024/0008188A
Other languages
English (en)
Spanish (es)
Inventor
Christian Hinderer
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of CO2024008188A2 publication Critical patent/CO2024008188A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CONC2024/0008188A 2021-12-24 2024-06-24 Terapia génica para deficiencias relacionadas con lámina a CO2024008188A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293680P 2021-12-24 2021-12-24
PCT/US2022/082383 WO2023122803A1 (en) 2021-12-24 2022-12-24 Gene therapy for lamin a - associated deficiencies

Publications (1)

Publication Number Publication Date
CO2024008188A2 true CO2024008188A2 (es) 2024-08-08

Family

ID=86903820

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0008188A CO2024008188A2 (es) 2021-12-24 2024-06-24 Terapia génica para deficiencias relacionadas con lámina a

Country Status (11)

Country Link
US (1) US20250049949A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453226A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025501768A (cg-RX-API-DMAC7.html)
KR (1) KR20240118821A (cg-RX-API-DMAC7.html)
CN (1) CN118434877A (cg-RX-API-DMAC7.html)
AU (1) AU2022419657A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241202A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024008188A2 (cg-RX-API-DMAC7.html)
IL (1) IL313734A (cg-RX-API-DMAC7.html)
MX (1) MX2024007903A (cg-RX-API-DMAC7.html)
WO (1) WO2023122803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
WO2025075551A1 (en) * 2023-10-06 2025-04-10 National University Of Singapore Method of treating lmna dilated cardiomyopathy
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291699B2 (en) * 2003-03-18 2007-11-06 The Regents Of The University Of Colorado Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders
WO2013071047A1 (en) * 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
US12404522B2 (en) * 2018-01-19 2025-09-02 Agency For Science, Technology And Research Disrupting the LINC complex for treating laminopathy
WO2020176896A1 (en) * 2019-02-28 2020-09-03 Encoded Therapeutics, Inc. Compositions and methods for treating laminopathies
EP4198053A1 (en) * 2021-12-15 2023-06-21 Universitätsklinikum Hamburg-Eppendorf Lmna gene expression for treatment of laminopathies

Also Published As

Publication number Publication date
WO2023122803A1 (en) 2023-06-29
MX2024007903A (es) 2024-07-10
US20250049949A1 (en) 2025-02-13
EP4453226A4 (en) 2026-03-18
JP2025501768A (ja) 2025-01-23
EP4453226A1 (en) 2024-10-30
CA3241202A1 (en) 2023-06-29
AU2022419657A1 (en) 2024-06-13
IL313734A (en) 2024-08-01
KR20240118821A (ko) 2024-08-05
CN118434877A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
MX2024007903A (es) Terapia genica para deficiencias relacionadas con lamina a.
CL2020001428A1 (es) Terapia genética para la mucopolisacaridosis iiib.
CO2021008538A2 (es) Composiciones para la reducción de la expresión transgénica específica de drg
BR112022015979A2 (pt) Vetores de terapia genética para tratamento de doenças cardíacas
CO2024001148A2 (es) Casetes de expresión optimizada para genoterapia
CN118979001A (zh) 经遗传修饰的细菌和用于细菌的遗传修饰的方法
NZ555830A (en) Chimeric vectors
CO2023009633A2 (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
BR112023024078A2 (pt) Produção de vetores de aav recombinantes para o tratamento de distrofia muscular
Dewi et al. Targeted therapy for skeletal muscle fibrosis: regulation of myostatin, TGF-β, MMP, and TIMP to maintain extracellular matrix homeostasis
DE69432486D1 (de) Huehner-anaemie-virus mutante, impfstoffe, und verwendung basiert auf virusproteinen vp1, vp2 und vp3, oder dafuer kodierende virus-sequenzen
BR112022026749A2 (pt) Polinucleotídeo isolado, polipeptídeo hexon, capsídeo adenoviral, adenovírus, partícula semelhante a vírus, vetor, composição, célula e método in vitro para a produção de um adenovírus ou de uma partícula semelhante a adenovírus
Li et al. A new approach to control condylar growth by regulating angiogenesis
MX2024005735A (es) Genoterapia para el tratamiento de la mucopolisacaridosis iii a
BR112022022615A2 (pt) Proteína nova e usos terapêuticos e cosméticos da mesma
CN107955803B (zh) 一种提高胰酶依赖性猪流行性腹泻病毒培养滴度的方法
Zhang et al. mRNA-based therapeutics in skin regeneration and rejuvenation: From optimization strategies to translational advances
Murgia et al. Reply to" Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the" minimal disease activity" parameter"
ZA202311480B (en) Therapeutic pharmaceutical composition for bone and soft tissue tumors
AR131813A1 (es) Terapia génica para el síndrome de angelman
Zieliński et al. Cellular response of MCF-7 and MCF--12A cell line to conventional versus ultra-high dose rate radiotherapy: analysis of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS)
Assis et al. Creation of a vascular inducing device using mesenchymal stem cells to induce angiogenesis
Guo et al. A highly infectious chimeric adenovirus expressing basic fibroblast growth factor exerts potent targeted therapy for rabbit ear chronic ischemic wounds
LI et al. Dosimetric differences in intensity modulated radiation therapy based on EUD and DV optimizations in lung cancer
CN119899871A (zh) 一种耐辐射腺病毒载体及构建方法